Cargando…

Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study

Atopic dermatitis (AD) has been shown to be closely related to gut dysbiosis mediated through the gut–skin axis, and thus the gut microbiome has recently been explored as a potential therapeutic target for the treatment of AD. Contrasting and varying efficacy have been reported since then. In order...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiwei, Choy, Chi Tung, Lin, Yufeng, Wang, Lin, Hou, Jinpao, Tsui, Joseph Chi Ching, Zhou, Junwei, Wong, Chi Ho, Yim, Tai Ki, Tsui, Wai Kai, Chan, Un Kei, Siu, Pui Ling Kella, Loo, Steven King Fan, Tsui, Stephen Kwok Wing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687608/
https://www.ncbi.nlm.nih.gov/pubmed/36428472
http://dx.doi.org/10.3390/biomedicines10112904
_version_ 1784836049187373056
author Wang, Yiwei
Choy, Chi Tung
Lin, Yufeng
Wang, Lin
Hou, Jinpao
Tsui, Joseph Chi Ching
Zhou, Junwei
Wong, Chi Ho
Yim, Tai Ki
Tsui, Wai Kai
Chan, Un Kei
Siu, Pui Ling Kella
Loo, Steven King Fan
Tsui, Stephen Kwok Wing
author_facet Wang, Yiwei
Choy, Chi Tung
Lin, Yufeng
Wang, Lin
Hou, Jinpao
Tsui, Joseph Chi Ching
Zhou, Junwei
Wong, Chi Ho
Yim, Tai Ki
Tsui, Wai Kai
Chan, Un Kei
Siu, Pui Ling Kella
Loo, Steven King Fan
Tsui, Stephen Kwok Wing
author_sort Wang, Yiwei
collection PubMed
description Atopic dermatitis (AD) has been shown to be closely related to gut dysbiosis mediated through the gut–skin axis, and thus the gut microbiome has recently been explored as a potential therapeutic target for the treatment of AD. Contrasting and varying efficacy have been reported since then. In order to investigate the determining factor of probiotics responsiveness in individuals with AD, we initiated the analysis of 41 AD patients with varying disease severity in Hong Kong, whereas the severity was assessed by Eczema Area and Severity Index (EASI) by board certified dermatologist. 16S rRNA sequencing on the fecal samples from AD patients were performed to obtain the metagenomics profile at baseline and after 8 weeks of oral administration of a novel E3 probiotics formula (including prebiotics, probiotics and postbiotics). While EASI of the participants were significantly lower after the probiotics treatment (p < 0.001, paired Wilcoxon signed rank), subjects with mild AD were found to be more likely to respond to the probiotics treatment. Species richness among responders regardless of disease severity were significantly increased (p < 0.001, paired Wilcoxon signed rank). Responders exhibited (1) elevated relative abundance of Clostridium, Fecalibacterium, Lactobacillus, Romboutsia, and Streptococcus, (2) reduced relative abundance of Collinsella, Bifidobacterium, Fusicatenibacter, and Escherichia-Shigella amid orally-intake probiotics identified using the machine learning algorithm and (3) gut microbiome composition and structure resembling healthy subjects after probiotics treatment. Here, we presented the gut microbiome dynamics in AD patients after the administration of the E3 probiotics formula and delineated the unique gut microbiome signatures in individuals with AD who were responding to the probiotics. These findings could guide the future development of probiotics use for AD management.
format Online
Article
Text
id pubmed-9687608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96876082022-11-25 Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study Wang, Yiwei Choy, Chi Tung Lin, Yufeng Wang, Lin Hou, Jinpao Tsui, Joseph Chi Ching Zhou, Junwei Wong, Chi Ho Yim, Tai Ki Tsui, Wai Kai Chan, Un Kei Siu, Pui Ling Kella Loo, Steven King Fan Tsui, Stephen Kwok Wing Biomedicines Article Atopic dermatitis (AD) has been shown to be closely related to gut dysbiosis mediated through the gut–skin axis, and thus the gut microbiome has recently been explored as a potential therapeutic target for the treatment of AD. Contrasting and varying efficacy have been reported since then. In order to investigate the determining factor of probiotics responsiveness in individuals with AD, we initiated the analysis of 41 AD patients with varying disease severity in Hong Kong, whereas the severity was assessed by Eczema Area and Severity Index (EASI) by board certified dermatologist. 16S rRNA sequencing on the fecal samples from AD patients were performed to obtain the metagenomics profile at baseline and after 8 weeks of oral administration of a novel E3 probiotics formula (including prebiotics, probiotics and postbiotics). While EASI of the participants were significantly lower after the probiotics treatment (p < 0.001, paired Wilcoxon signed rank), subjects with mild AD were found to be more likely to respond to the probiotics treatment. Species richness among responders regardless of disease severity were significantly increased (p < 0.001, paired Wilcoxon signed rank). Responders exhibited (1) elevated relative abundance of Clostridium, Fecalibacterium, Lactobacillus, Romboutsia, and Streptococcus, (2) reduced relative abundance of Collinsella, Bifidobacterium, Fusicatenibacter, and Escherichia-Shigella amid orally-intake probiotics identified using the machine learning algorithm and (3) gut microbiome composition and structure resembling healthy subjects after probiotics treatment. Here, we presented the gut microbiome dynamics in AD patients after the administration of the E3 probiotics formula and delineated the unique gut microbiome signatures in individuals with AD who were responding to the probiotics. These findings could guide the future development of probiotics use for AD management. MDPI 2022-11-11 /pmc/articles/PMC9687608/ /pubmed/36428472 http://dx.doi.org/10.3390/biomedicines10112904 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Yiwei
Choy, Chi Tung
Lin, Yufeng
Wang, Lin
Hou, Jinpao
Tsui, Joseph Chi Ching
Zhou, Junwei
Wong, Chi Ho
Yim, Tai Ki
Tsui, Wai Kai
Chan, Un Kei
Siu, Pui Ling Kella
Loo, Steven King Fan
Tsui, Stephen Kwok Wing
Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study
title Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study
title_full Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study
title_fullStr Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study
title_full_unstemmed Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study
title_short Effect of a Novel E3 Probiotics Formula on the Gut Microbiome in Atopic Dermatitis Patients: A Pilot Study
title_sort effect of a novel e3 probiotics formula on the gut microbiome in atopic dermatitis patients: a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687608/
https://www.ncbi.nlm.nih.gov/pubmed/36428472
http://dx.doi.org/10.3390/biomedicines10112904
work_keys_str_mv AT wangyiwei effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT choychitung effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT linyufeng effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT wanglin effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT houjinpao effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT tsuijosephchiching effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT zhoujunwei effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT wongchiho effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT yimtaiki effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT tsuiwaikai effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT chanunkei effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT siupuilingkella effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT loostevenkingfan effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy
AT tsuistephenkwokwing effectofanovele3probioticsformulaonthegutmicrobiomeinatopicdermatitispatientsapilotstudy